Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
University of Alabama at Birmingham
Summary
This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (RT) with or without concurrent temozolomide (TMZ). Study participants will undergo simultaneous positron emission tomography/magnetic resonance imaging (PET/MRI) with O-(\[2-\[F-18\]fluoroethyl)-L-tyrosine (FET, amino acid transport) and 1H-1-(3-\[F-18\]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO, hypoxia) at the time of standard of care imaging after completion of RT. The presence of viable tumor at this time point will be assessed on a per patient basis. Study participants will be followed clinically and with standard of care (SOC) imaging for up to 2 years after completion of PET/MRI to determine the nature of lesions seen on investigational imaging and to obtain patient outcome data. The imaging data will also be used to develop a semi-automated workflow suitable for implementation in clinical trials and standard of care PET/MRI studies.
Description
Patient recruitment Potential participants will be identified through the UAB and Children's of Alabama (CoA) Neuro-Oncology, Neurosurgery and Radiation Oncology services. Patients seen in UAB clinics and/or discussed in multi-disciplinary neuro-oncology tumor board meetings may be approached to participate in this study. Potential participants can be enrolled from the time that the plan for standard of care therapy is selected through the time of the first standard of care of MRI after radiation therapy. Given that high grade gliomas are much more frequent in adults than children, we expect…